|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.6 USD | +1.76% |
|
+3.00% | +5.74% |
April 8 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,630 JPY | +0.23% | +0.80% | 8.94B | ||
| 161.5 USD | +1.19% | -3.79% | 283B | ||
| 30.6 USD | +1.76% | +3.00% | 1.65B | ||
| 0.9 USD | +23.29% | +95.65% | 529K | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +5.74% | 1.65B | |
| +4.06% | 70.44B | |
| +10.97% | 8.94B | |
| -14.44% | 4.75B | |
| +41.60% | 4.5B | |
| +5.96% | 3.85B | |
| +23.46% | 2.38B | |
| -19.32% | 2.34B | |
| -27.04% | 2.2B | |
| +7.97% | 1.96B |
SUPERNUS PHARMACEUTICALS, INC. 
